WAM Leaders thinks these ASX shares might be buys

ResMed is one of the ASX shares that WAM Leaders likes at the moment.

| More on:
2021 logo with an arrow representing growth and watering the arrow

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Respected fund manager Wilson Asset Management (WAM) has recently identified two ASX shares that it owns in its portfolio.

WAM operates several listed investment companies (LICs). Two of those LICs are WAM Capital Limited (ASX: WAM) and WAM Research Limited (ASX: WAX).

There's also one called WAM Leaders Ltd (ASX: WLE) which looks at the larger businesses on the ASX.

WAM says WAM Leaders actively invests in the highest quality Australian companies.

The WAM Leaders portfolio has delivered gross returns (that's before fees, expenses and taxes) of 14.9% per annum since inception in May 2016, which is superior to the S&P/ASX 200 Accumulation Index average return of 10.4%.

These are the ASX shares that WAM outlined in its most recent monthly update:

ResMed Inc (ASX: RMD)

WAM Leaders says that ResMed is a respiratory device manufacturer and medical software as a service (SaaS) provider.

The fund manager noted that the company experienced a significant rise during June largely as a result of Philips, a key competitor in the obstructive sleep apnea (OSA) industry, announcing a recall of 3 million to 4 million CPAP (continuous positive airway pressure) devices manufactured between 2009 and 2021 due to foam degradation issues.

WAM expects the ASX share to experience an increase in demand for devices as a result of this, which should aid in offsetting the channel destocking event that would usually occur ahead of the launch of a new device. Despite the recent share price momentum, the fund manager continues to be positive about the long-term outlook for ResMed as it expects performance market share gains to arise from Philips' reputational damage and the upcoming 'AirSense 11' launch later this calendar year to drive revenue higher.

The fund manager believes the ASX share's valuation compared to the growth outlook of ResMed is more attractive than its large healthcare peers.

According to Commsec, the ResMed share price is valued at 38x FY23's estimated earnings.

Cochlear Limited (ASX: COH)

WAM Leaders described Cochlear as a business that manufactures cochlear implant devices to hearing impaired children and adults.

The fund manager pointed that that Cochlear is benefiting from a situation of a similar nature to ResMed. Recent data points suggest Cochlear continues to benefit from market share gains as a result of competitor Advanced Bionics, which is part of Sonova, announcing a recall of some of its cochlear implant devices in February 2020.

The reputational damage of a recall is significant, as the faulty devices require surgical explanting, and in paediatrics can significantly impede speech development, according to WAM.

On top of that, WAM Leaders also said that the ASX share remains a clear winner of the reopening trade and recent feedback from US audiologists suggest cochlear implant patient numbers are strongly above pre-COVID levels. It also said that patient numbers in the quarter ending 30 June 2021 was well above the 2020 calendar year.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Woman in celebratory fist move looking at phone
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A female financial services professional with a manicured black afro hairstyle turns an ipad screen to show a client across the table a set of ASX shares figures in graph format.
Share Market News

Record CBA share price and blockbuster merger push ASX 200 financials sector to the top

ASX financial stocks led the 11 market sectors last week with a 1.95% gain.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Market News

CBA Shares in focus: How Australia's most valuable company is using AI to compete

Could AI initiatives drive CBA shares higher?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Broker Notes

These ASX 200 shares could rise 20% to 50%

Looking for big returns? Brokers think these shares could do the job.

Read more »

asx share price represented by cartoon letters spelling the word FOMO
Share Market News

What did Macquarie's "FOMO Meter" reveal about the stock market in May?

Is the market getting frothy or is there still room to climb?

Read more »

Market up or down
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the week...

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Share Gainers

4 ASX 200 shares racing ahead of the benchmark this week

ASX investors sent these four stocks soaring 12% to 18% this week. But why?

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »